BeOne Medicines Statistics

Total Valuation

BeOne Medicines has a market cap or net worth of HKD 276.65 billion. The enterprise value is 263.11 billion.

Market Cap	276.65B
Enterprise Value	263.11B

Important Dates

The last earnings date was Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.32B
Shares Outstanding	n/a
Shares Change (YoY)	+2.33%
Shares Change (QoQ)	+1.25%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	67.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	107.68
PS Ratio	7.73
PB Ratio	9.35
P/TBV Ratio	9.51
P/FCF Ratio	143.94
P/OCF Ratio	61.70
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-188.68
EV / Sales	7.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	136.90

Financial Position

The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.27.

Current Ratio	1.95
Quick Ratio	1.65
Debt / Equity	0.27
Debt / EBITDA	8.77
Debt / FCF	4.19
Interest Coverage	-4.70

Financial Efficiency

Return on equity (ROE) is -4.98% and return on invested capital (ROIC) is -1.37%.

Return on Equity (ROE)	-4.98%
Return on Assets (ROA)	-1.06%
Return on Invested Capital (ROIC)	-1.37%
Return on Capital Employed (ROCE)	-2.48%
Revenue Per Employee	3.26M
Profits Per Employee	-126,770
Employee Count	11,000
Asset Turnover	0.76
Inventory Turnover	1.59

Taxes

In the past 12 months, BeOne Medicines has paid 898.31 million in taxes.

Income Tax	898.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +71.90% in the last 52 weeks. The beta is 0.27, so BeOne Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+71.90%
50-Day Moving Average	166.49
200-Day Moving Average	142.55
Relative Strength Index (RSI)	63.52
Average Volume (20 Days)	6,199,582

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.71

Income Statement

In the last 12 months, BeOne Medicines had revenue of HKD 35.81 billion and -1.39 billion in losses. Loss per share was -13.05.

Revenue	35.81B
Gross Profit	29.91B
Operating Income	-796.88M
Pretax Income	-496.16M
Net Income	-1.39B
EBITDA	621.33M
EBIT	-796.88M
Loss Per Share	-13.05

Full Income Statement

Balance Sheet

The company has 21.63 billion in cash and 8.05 billion in debt, giving a net cash position of 13.58 billion.

Cash & Cash Equivalents	21.63B
Total Debt	8.05B
Net Cash	13.58B
Net Cash Per Share	n/a
Equity (Book Value)	29.60B
Book Value Per Share	269.41
Working Capital	16.49B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.48 billion and capital expenditures -2.56 billion, giving a free cash flow of 1.92 billion.

Operating Cash Flow	4.48B
Capital Expenditures	-2.56B
Free Cash Flow	1.92B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 83.51%, with operating and profit margins of -2.23% and -3.89%.

Gross Margin	83.51%
Operating Margin	-2.23%
Pretax Margin	-1.39%
Profit Margin	-3.89%
EBITDA Margin	1.74%
EBIT Margin	-2.23%
FCF Margin	5.37%

Dividends & Yields

BeOne Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.33%
Shareholder Yield	n/a
Earnings Yield	-0.50%
FCF Yield	0.69%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BeOne Medicines has an Altman Z-Score of 4.71 and a Piotroski F-Score of 5.

Altman Z-Score	4.71
Piotroski F-Score	5